Last reviewed · How we verify
CC-122
CC-122 is a selective inhibitor of the immunoproteasome.
CC-122 is a selective inhibitor of the immunoproteasome. Used for Multiple myeloma.
At a glance
| Generic name | CC-122 |
|---|---|
| Also known as | Avadomide, BMS-986381 |
| Sponsor | Celgene |
| Drug class | Immunoproteasome inhibitor |
| Target | Immunoproteasome |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CC-122 works by inhibiting the immunoproteasome, which is involved in the processing and presentation of antigens to the immune system. This leads to a decrease in the production of pro-inflammatory cytokines and an increase in the production of anti-inflammatory cytokines.
Approved indications
- Multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Rollover Study of CC-122 (PHASE1)
- A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL) (PHASE1)
- A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PHASE1, PHASE2)
- Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma (PHASE1)
- Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma (PHASE1)
- A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. (PHASE1)
- Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma (PHASE2)
- A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CC-122 CI brief — competitive landscape report
- CC-122 updates RSS · CI watch RSS
- Celgene portfolio CI